null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal debt; cash-funded clinical-stage biotech with ~$50M+ cash runway; leverage ratio near zero, minimal interest rate exposure

Low sensitivity; no significant floating-rate debt; higher rates marginally increase opportunity cost of held cash and equity dilution risk

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) CMO/CDMO concentration in US/Europe for Wnt-pathway biologics synthesis; 2) API raw material sourcing potentially tied to Chinese chemical suppliers

Preclinical/early clinical stage; no international revenue; no sovereign currency devaluation exposure currently

US-only operations; no international revenue markets; currency devaluation exposure is effectively zero at this stage

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or dual CDMO partners for biologic drug substance manufacturing; substitution would cause 12-18 month delays

Cloud disruption would impair R&D data pipelines and computational biology workflows but would not halt clinical trials immediately

30-day cloud termination would require emergency migration; estimated 2-4 week operational disruption; no direct patient safety risk short-term

Moderate API/platform coupling risk in bioinformatics tools; proprietary Wnt pathway screening platform creates internal lock-in rather than vendor coupling

Revenue model is pharma licensing/milestones, not securities-like instruments; Howey Test largely inapplicable; low regulatory reclassification risk

Very High

Limited patient data exposure pre-commercialization; clinical trial data governed by FDA/ICH GCP; GDPR exposure minimal given US-centric trials

Low antitrust risk; niche Wnt pathway biologics space; no dominant market position; competitive landscape includes Roche, AbbVie in adjacent areas

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based; partnership revenue from AstraZeneca deal is milestone-contingent, not recurring subscription revenue

Biopharmaceutical licensing milestones and royalties; primary AstraZeneca collaboration for GI/liver indications worth up to ~$1B+ in milestones

No commercial pricing yet; future drug pricing will follow specialty biologics model (~$50K-$200K/year), subject to payer negotiation and FDA approval

Moderate-high potential pricing power if approved for rare/orphan GI indications; Wnt pathway differentiation supports premium positioning

Projected 80-90% gross margin at commercialization assuming royalty/licensing model; manufacturing COGS would compress if self-commercializing

No free-rider leakage problem; proprietary biologics IP protected by patents; partnership revenue is contractually structured with defined milestones

R&D headcount-linear growth required through Phase 2/3; post-approval commercialization via partners would decouple revenue from headcount

Marginal cost of revenue growth is high pre-commercialization (clinical trial costs); post-licensing deal execution, marginal cost drops significantly

null

At 10x scale (multiple approved drugs), CAC irrelevant; partner acquisition cost per deal estimated $5-20M in BD spend; NPV positive at milestone values

No meaningful network effects; value derived from IP moats and biological platform differentiation, not user network density

-245.2% Return on Assets (Negative equity)

Moderate recession resistance; clinical funding dependent on capital markets; partnership revenue somewhat insulated but new deal flow would slow

Large pharmaceutical/biotech partners (e.g., AstraZeneca) for licensing; extreme concentration risk with single dominant partner

Future: specialty GI and hepatology patient populations via licensing partners; no direct B2C or hospital customer relationships currently

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

3.7% CapEx / Revenue (Low-CapEx Asset-Light)

0001824893

SRZN